TuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a report released on Sunday.

Other equities research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.00.

TuHURA Biosciences Stock Up 8.4%

NASDAQ:HURA opened at $1.94 on Friday. The business’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.67. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $4.44. The company has a market cap of $117.80 million, a PE ratio of -3.88 and a beta of -0.33.

Institutional Trading of TuHURA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares during the last quarter. Deutsche Bank AG lifted its stake in TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of TuHURA Biosciences during the second quarter valued at $97,000. Goldman Sachs Group Inc. acquired a new position in shares of TuHURA Biosciences during the fourth quarter valued at $30,000. Finally, Marshall Wace LLP acquired a new position in shares of TuHURA Biosciences during the second quarter valued at $79,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.